latrepirdine has been researched along with alpha-synuclein in 4 studies
| Studies (latrepirdine) | Trials (latrepirdine) | Recent Studies (post-2010) (latrepirdine) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 126 | 7 | 59 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anichtchik, O; Bachurin, SO; Buchman, VL; Millership, S; Ninkina, NN; Peters, O; Shelkovnikova, TA; Spillantini, MG; Ustyugov, AA | 1 |
| Alfaro, IE; Barr, R; Bernales, S; Bharadwaj, P; Buxbaum, JD; Delgado, LM; Dolios, G; Ehrlich, ME; Fraser, P; Friss, A; Gandy, S; Glabe, CG; Gupta, V; Ju, S; Kim, SH; Lachenmayer, ML; Liken, J; Martins, RN; Petsko, GA; Protter, AA; Relkin, NR; Ringe, D; St George-Hyslop, PH; Steele, JW; Stock, A; Szabo, P; Verdile, G; Wang, R; Westaway, D; Yue, Z | 1 |
| Alfaro, IE; Barr, R; Bernales, S; Bharadwaj, P; Delgado, LM; Dolios, G; Ehrlich, ME; Friss, A; Gandy, S; Gupta, V; Ju, S; Kim, SH; Lachenmayer, ML; Liken, J; Martins, RN; Petsko, GA; Protter, AA; Ringe, D; Steele, JW; Stock, A; Verdile, G; Wang, R; Yue, Z | 1 |
| Gandy, S; Steele, JW | 1 |
4 other study(ies) available for latrepirdine and alpha-synuclein
| Article | Year |
|---|---|
Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Biomarkers; Blotting, Western; Brain Chemistry; Cell Count; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Exploratory Behavior; Gene Expression; Histamine; Humans; Immunohistochemistry; Indoles; Mice; Mice, Transgenic; Motor Activity; Neurons; Olfactory Bulb; Postural Balance; RNA; Ventral Tegmental Area | 2011 |
Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Autophagy-Related Protein 5; Brain; Cells, Cultured; Cognition; Dose-Response Relationship, Drug; Indoles; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Neuroprotective Agents; Peptide Fragments; Signal Transduction; TOR Serine-Threonine Kinases | 2013 |
Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.
Topics: alpha-Synuclein; Amyloid beta-Peptides; Animals; Autophagy; Brain; Cell Death; Cells, Cultured; Humans; Indoles; Male; Mice; Neuroprotective Agents; Peptide Fragments; Saccharomyces cerevisiae | 2013 |
Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Disease Models, Animal; Humans; Indoles; Mice; Mice, Transgenic; Neurons | 2013 |